What is Zacks Research’s Forecast for IOVA Q1 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the biotechnology company will earn ($0.21) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.20) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $86.77 million for the quarter, compared to the consensus estimate of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%.

A number of other research analysts also recently weighed in on the stock. UBS Group increased their target price on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. Barclays lifted their price target on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Wall Street Zen upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Chardan Capital decreased their target price on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $8.88.

Iovance Biotherapeutics Stock Performance

NASDAQ IOVA opened at $3.87 on Thursday. The company has a market capitalization of $1.59 billion, a PE ratio of -3.46 and a beta of 0.69. Iovance Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $5.63. The company has a 50-day simple moving average of $3.17 and a 200 day simple moving average of $2.61.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IOVA. Rockefeller Capital Management L.P. lifted its stake in Iovance Biotherapeutics by 187.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 50,726 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 33,091 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Iovance Biotherapeutics by 658.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 47,277 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 41,047 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Iovance Biotherapeutics by 32.4% in the fourth quarter. Invesco Ltd. now owns 1,251,665 shares of the biotechnology company’s stock worth $3,417,000 after purchasing an additional 306,195 shares during the period. XTX Topco Ltd raised its position in shares of Iovance Biotherapeutics by 148.4% in the fourth quarter. XTX Topco Ltd now owns 522,934 shares of the biotechnology company’s stock worth $1,428,000 after buying an additional 312,413 shares in the last quarter. Finally, VARCOV Co. purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter worth $253,000. Institutional investors own 77.03% of the company’s stock.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks raised multiple 2026 quarterly EPS forecasts (Q1 2026 to ($0.21) from ($0.22); Q2 2026 to ($0.19) from ($0.20); Q3 2026 to ($0.16) from ($0.17); Q4 2026 to ($0.14) from ($0.16)) and boosted FY2026 to ($0.69) from ($0.74), signaling an improved near-term loss trajectory that can support the stock. MarketBeat Report
• Neutral Sentiment: Zacks published a FY2028 estimate of ($0.20) per share (a new/forward-looking projection) — useful for modeling but not an immediate catalyst. MarketBeat Report
• Negative Sentiment: Zacks trimmed several 2027 quarterly estimates (Q2 2027 to ($0.14) from ($0.13); Q3 2027 to ($0.10) from ($0.09); Q4 2027 to ($0.08) from ($0.07)) and lowered FY2027 to ($0.47) from ($0.45), indicating expectations for a slower improvement in 2027 and creating downside risk for valuation. MarketBeat Report

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.